# Nplate (romiplostim) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/romiplostim

> The next catalyst for Nplate (romiplostim), sponsored by AMGEN INC (AMGN), is its topline data readout, Sep to Dec 2029.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Nplate (romiplostim) |
| Codes | AMG-531 |
| Sponsor | AMGEN INC (AMGN) https://sec-api.dev/companies/amgn/catalysts |
| Indications | Chemotherapy-induced Thrombocytopenia, [Primary Immune Thrombocytopenia](https://sec-api.dev/indications/primary-immune-thrombocytopenia) |
| Modality | biologic |
| FDA designations | priority review |

## Timeline

### January 28, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125268 SUPPL-167 (Efficacy): submission_status AP, submission_status_date 20210128, review_priority PRIORITY; sponsor_name AMGEN; product NPLATE (ROMIPLOSTIM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125268%22

### March 10, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Chemotherapy-induced Thrombocytopenia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03937154 (Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-10 (ACTUAL); Lead Sponsor Amgen." https://clinicaltrials.gov/study/NCT03937154

### Sep to Dec 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Primary Immune Thrombocytopenia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07700238 (A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-14 (ESTIMATED); Lead Sponsor Amgen." https://clinicaltrials.gov/study/NCT07700238

### September 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Primary Immune Thrombocytopenia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07700238 (A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-14 (ESTIMATED); Lead Sponsor Amgen." https://clinicaltrials.gov/study/NCT07700238

## Same indication

- [VYVGART (efgartigimod)](https://sec-api.dev/pdufa/efgartigimod) (ARGX)
- [Efgartigimod ph20 sc](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) (ARGX)
- [Ianalumab](https://sec-api.dev/pdufa/ianalumab) (NVS)
- [PF-06835375](https://sec-api.dev/pdufa/pf-06835375) (PFE)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/romiplostim.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Nplate (romiplostim) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/romiplostim

```bibtex
@misc{secapidev_pdufa_romiplostim_20261116,
  title        = {Nplate (romiplostim) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/romiplostim}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_romiplostim_20261116","title":"Nplate (romiplostim) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/romiplostim","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
